Expansion Opportunity Althea has recently expanded facilities in San Diego with a 57,000-sf pharmaceutical manufacturing footprint, signaling capacity growth and potential for new CDMO partnerships, especially for complex biologics and aseptic fill-finish programs that require scalable manufacturing capabilities.

Aseptic Fill Finish The company highlights expertise in drug formulation and aseptic fill finish for vials and syringes, presenting a clear entry point for partnerships in sterile manufacturing, packaging optimization, and fill-finish projects for biologics, vaccines, and high-potency products.

Mid Market Scale With revenue in the $100M-$250M range and a moderate employee base, Althea sits in the mid-market CDMO segment, offering a compelling value proposition for biotech firms scaling from research to early commercial phases seeking reliable, full-service development and manufacturing in one location.

Policy and Compliance Recent facility expansions and the presence of dedicated GMP production suites indicate strong regulatory readiness. This can be leveraged to target sponsors seeking compliant partners for cGMP development, clinical manufacturing, and fast-track programs requiring robust quality systems.

Strategic Fit Althea’s integrated model covering process development, drug substance manufacturing, and drug product manufacturing in a single site aligns well with sponsors needing end-to-end support, reducing supply chain risk and accelerating timelines for early-stage to commercial manufacturing.